Health Economics›Colorectal cancer›Metastatic disease first-line

Metastatic disease first-line

Colorectal cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FOLFOX chronotherapy Variant #01	—	R 6 310	21d	—	—	~2	~R 12 619 indirect	—
Fluorouracil and Mitomycin Variant #01	—	R 1 432	42d	—	—	~35	~R 50 131 indirect	—
Fluorouracil and Methotrexate (MF) Variant #01	—	R 948	28d	—	—	~3	~R 2 369 indirect	—
Fluorouracil and Semustine Variant #01 Partial	—	R 364	42d	—	—	~2	~R 728 indirect	—
Best supportive care Partial	—	—	—	~1.7 mo	~4.6 mo	—	—	4
Raltitrexed monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—

6 of 6 regimens shown